- Home
- AREC vs ABOS Comparison
AREC vs ABOS Comparison
Compare AREC & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AREC | ABOS |
|---|---|---|
| Founded | 2013 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.5M | 197.9M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AREC | ABOS |
|---|---|---|
| Price | $2.47 | $3.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $6.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.9M | 349.7K |
| Earning Date | 06-01-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 223.53 | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $38,462.50 | N/A |
| P/E Ratio | $3.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.48 | $1.21 |
| 52 Week High | $7.11 | $3.60 |
Technical Indicators
Market Signals| Indicator | AREC | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 51.41 | 66.61 |
| Support Level | $2.41 | $2.13 |
| Resistance Level | $2.53 | $3.34 |
| Average True Range (ATR) | 0.15 | 0.19 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 36.79 | 71.55 |
Price Performance
Historical ComparisonAbout AREC American Resources Corporation
American Resources Corp is engaged in the aggregation, recovery, recycling, and sale of recovered metal and steel materials. The company operates through two segments: Corporate and Electrified Materials. The Electrified Materials segment focuses on processing and recycling recovered metal and steel products.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.